Effects of esketamine on postoperative pain, anxiety, depression, sleep, and inflammation in pregnancies undergoing cesarean section: A randomized controlled trial.
Yijun Wang, Xiaolu Lin, Xiang Zou, Renqin Zhang, Juanxia Xing, Li Zhang, Jie Shen, Xiaoliang Zhang, Daju Zhou, Junhua Zhang
PLoS One 2026 DOI: 10.1371/journal.pone.0328585 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 98 |
| Population | Single-term pregnant women scheduled for elective cesarean section at Chongqing University Fuling Hospital |
| Interventions | Esketamine Sufentanil |
| Dose | 0.5 mg/kg esketamine intravenous bolus + 0.5 mg/kg in patient-controlled intravenous analgesia; control received normal saline + 4 μg/kg sufentanil PCIA |
| Duration | 24 hours postoperative for primary outcome; follow-up through postoperative day 2 |
| Topics | Anxiety Depression Esketamine |
| Key findings | Intravenous esketamine significantly reduced postoperative pain, psychological disorders, and inflammation after cesarean section compared to standard sufentanil alone. |
Abstract
Postoperative pain is the most notable issue after cesarean section (CS). The contributing factors include hyperalgesia, anxiety, depression, sleep disorders, and inflammation. In this study, we explored the effects of esketamine on pain, hyperalgesia, depression, anxiety, sleep disorders, and inflammation after CS. This randomized, blinded, controlled trial enrolled single-term pregnant women scheduled for elective CS. This trial was a single-center study conducted at Chongqing University Fuling Hospital. A simple randomization method was used. SPSS version 26.0 generated random numbers. The participants were randomly included in the esketamine group (group E: intravenous esketamine 0.5 mg/kg + sufentanil 4 μg/kg followed by patient-controlled intravenous analgesia with esketamine 0.5 mg/kg) or the control group (C: normal saline + sufentanil 4 μg/kg PCIA). The primary outcome was the maximum pain numerical rating scale (NRS) score within 24 h postoperatively. The secondary outcomes included pain NRS scores for moving incision, visceral, and rest incision pain at 0-6 h, 6-12 h and 12-24 h; pressure pain threshold and tolerance at 30 min and 24 h postoperatively; PCIA drug consumption, number of compressions, and dosage of rescue analgesics; time to first PCIA compression; serum C-reactive protein (CRP) at 24 h; incidence of drug-related side effects; and rates of anxiety, depression, and sleep disorders on postoperative day 2. Ninety-eight women were randomly included in group E (n = 50) or C (n = 48). Group E showed significantly lower maximum NRS pain scores within 24 h (5 [4-5] vs. 6 [5-6], P < 0.0001) and relieved rest incision, visceral, and moving incision pain at all time points. The PCIA compression was significantly delayed and CRP levels, as well as the incidence of postoperative depression, anxiety, and sleep disorders, were lower in group E. There were no statistically significant differences in hyperalgesia or side effects between the groups. Intravenous esketamine could effectively reduce postoperative pain, psychological disorders, and inflammation after CS. This study was registered in the Chinese Clinical Trial Registry with registration number ChiCTR2300078310.
Comparable studies
Other randomized controlled trials on esketamine for anxiety, most cited first.